November 3, 2003
As reported in The Wall Street Journal, Willkie client Teva Pharmaceuticals Inc. purchases Irvine, Calif-based Sicor for $3.4 billion.
As reported in the November 3 edition of The Wall Street Journal, it was announced on October 31 that Willkie client Teva Pharmaceuticals Inc. purchased Irvine, Calif-based Sicor for $3.4 billion. Teva, an Israeli company that produces generic drugs and the multiple sclerosis medicine Copaxone, will exchange $16.50 in cash and 0.1906 share of its American Depositary Receipts for each Sicor share. Through the deal, Teva will gain Sicor’s expertise in generic injectable drugs and capabilities in duplicating the wave of biotechnology drugs that are coming on the market. Willkie’s role is the deal was reported in the November 3 Daily Deal. As noted in the November 13 New York Law Journal, Willkie attorneys on the deal included, partners Peter Jakes, Jeffrey Hochman, Frank Daniele, Andrew Needham, E. Donald Elliott, Theodore Whitehouse; special counsel Jonathan Konoff; and associates Laly David, Christine DiVincent, Frank Gerhard, Moishie Klein, Arthur Rheingold, Eric Rosenoff, David Rubinsky, Eran Sarig, and Dong Shon.
